11:31 AM EST - Resverlogix Corp. : Announced that findings of a study performed by the Baker IDI Heart and Diabetes Institute and Resverlogix has been published in the journal 'Metabolism', titled: "Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial." Resverlogix Corp.
shares T.RVX are trading unchanged at $1.25.
